Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dose Finding and Randomized, Multicenter, Placebo-Controlled, Phase 2 Study of Enzastaurin and Sunitinib Versus Placebo and Sunitinib in Patients With Metastatic Renal Cell Carcinoma.

Trial Profile

Dose Finding and Randomized, Multicenter, Placebo-Controlled, Phase 2 Study of Enzastaurin and Sunitinib Versus Placebo and Sunitinib in Patients With Metastatic Renal Cell Carcinoma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Dec 2018

At a glance

  • Drugs Enzastaurin (Primary) ; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 12 Dec 2018 This trial has been completed in Poland (end date: 2018-09-05)
    • 20 Oct 2018 This trial has been completed in France (end date: 2018-09-07)
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top